Immunotherapy startup CytomX raises $70M; IPO on horizon
The Bay Area immunotherapy player targets PD-L1 and "Probody" drug conjugates. It'll use the $70 million to advance several candidates into the clinic.
The Bay Area immunotherapy player targets PD-L1 and "Probody" drug conjugates. It'll use the $70 million to advance several candidates into the clinic.
Swiss drugmaker Novartis just got Food and Drug Administration approval to sell the first pill that can slow the progression of multiple sclerosis. Gilenya will go head-to-head with injectable medicines, including Avonex, Tysabri and Rebif. But how much will the MS pill cost? Novartis won't say, NPR reports.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.